1-6 of 6
Nelson Guerreiro
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, Jeanette Fuchs, Emilie A. Chapeau, Markus Wartmann, Dario Sterker, Vincent Romanet, Masato Murakami, Grainne Kerr, Eric Y. Durand, Swann Gaulis, Marta Cortes-Cros, Stephan Ruetz, Therese-Marie Stachyra, Joerg Kallen, Pascal Furet, Jens Würthner, Nelson Guerreiro, Ensar Halilovic, Astrid Jullion, Audrey Kauffmann, Emil Kuriakose, Marion Wiesmann, Michael R. Jensen, Francesco Hofmann, William R. Sellers
Journal: Cancer Research
Series: Author Choice
Cancer Res (2018) 78 (21): 6257–6267.
https://doi.org/10.1158/0008-5472.CAN-18-0338
Published: 01 November 2018
View article titled, Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201
Open the PDF for Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201 in another window
Includes: Supplementary data
Journal Articles

Abstract CT009: Results of a dose- and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcoma

Albiruni Abdul Razak, Sebastian Bauer, Jean-Yves Blay, Richard Quek, Cristina Suárez, Chia-Chi Lin, Marie L. Hütter-Krönke, Ricardo Cubedo, Stephane Ferretti, Christophe Meille, Ensar Halilovic, Giorgia Clementi, Maria Santos-Rosa, Nelson Guerreiro, Astrid Jullion, Claire Fabre, Antoine Italiano
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT009.
https://doi.org/10.1158/1538-7445.AM2018-CT009
Published: 01 July 2018
View article titled, Abstract CT009: Results of a dose- and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcoma
Journal Articles

Abstract CT150: Optimizing the therapeutic index of HDM2 inhibition: Results from a dose- and regimen-finding Phase I study of NVP-HDM201 in pts with TP53 wt advanced tumors

David M. Hyman, Manik Chatterjee, Filip de Vos, Chia-Chi Lin, Cristina Suárez, David Tai, Philippe Cassier, Noboru Yamamoto, Vincent A. de Weger, Sébastien Jeay, Christophe Meille, Ensar Halilovic, Luisa Mariconti, Matthieu Klopfenstein, Nelson Guerreiro, Rajkumar Radhakrishnan, Emil T. Kuriakose, Sebastian Bauer
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT150.
https://doi.org/10.1158/1538-7445.AM2017-CT150
Published: 01 July 2017
View article titled, Abstract CT150: Optimizing the therapeutic index of HDM2 inhibition: Results from a dose- and regimen-finding Phase I study of NVP-HDM201 in pts with <em>TP53</em> wt advanced tumors
Journal Articles

Abstract CT152: Phase I dose- and regimen-finding study of NVP-HDM201 in pts with advanced TP53 wt acute leukemias

Eytan Stein, Joerg Chromik, Daniel J. DeAngelo, Manik Chatterjee, Richard Noppeney, Filip de Vos, Hironobu Minami, Sébastien Jeay, Christophe Meille, Ensar Halilovic, Luisa Mariconti, Matthieu Klopfenstein, Nelson Guerreiro, Rajkumar Radhakrishnan, Emil T. Kuriakose, Cecilia Carpio
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT152.
https://doi.org/10.1158/1538-7445.AM2017-CT152
Published: 01 July 2017
View article titled, Abstract CT152: Phase I dose- and regimen-finding study of NVP-HDM201 in pts with advanced <em>TP53</em> wt acute leukemias
Journal Articles

Abstract CT154: Optimization of the dose and schedule of an HDM2 inhibitor NVP-HDM201 in a first-in-human Phase I study using a mechanism-based PK/PD model

Christophe Meille, Nelson Guerreiro, Astrid Jullion, Sebastian Bauer, Manik Chatterjee, Filip de Vos, Chia-Chi Lin, Cristina Suárez Rodríguez, David Tai, Philippe Cassier, Noboru Yamamoto, Vincent A. de Weger, Matthieu Klopfenstein, Luisa Mariconti, Emil T. Kuriakose, David M. Hyman
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT154.
https://doi.org/10.1158/1538-7445.AM2017-CT154
Published: 01 July 2017
View article titled, Abstract CT154: Optimization of the dose and schedule of an HDM2 inhibitor NVP-HDM201 in a first-in-human Phase I study using a mechanism-based PK/PD model
Journal Articles

Abstract 1225: NVP-HDM201: cellular and in vivo profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2

Sébastien Jeay, Patrick Chène, Stéphane Ferretti, Pascal Furet, Bjoern Gruenenfelder, Vito Guagnano, Nelson Guerreiro, Ensar Halilovic, Francesco Hofmann, Joerg Kallen, Michelle Léonard, Robert Mah, Keiichi Masuya, Rita Ramos, Caroline Rynn, Stephan Ruetz, Thérèse Stachyra-Valat, Stefan Stutz, Andrea Vaupel, Jens Wuerthner, Philipp Holzer
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 1225.
https://doi.org/10.1158/1538-7445.AM2016-1225
Published: 15 July 2016
View article titled, Abstract 1225: NVP-HDM201: cellular and in vivo profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2